ArticlePediatric blood & cancer2019
Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
Article in Pediatric blood & cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non-Clinical Evidence, and Regulatory Science.Journal of clinical pharmacology · 2026Review
- Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.Cancer medicine · 2024Article
- The Battlefield of Chemotherapy in Pediatric Cancers.Cancers · 2023Review
- The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children.Journal of clinical medicine · 2023Review
- Pediatric oncology drug development and dosage optimization.Frontiers in oncology · 2023Review
- The use of special approval medicines among pediatric patients in a tertiary care hospital: A reality check.Exploratory research in clinical and social pharmacy · 2022Article
- The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy.Journal of hematology & oncology · 2022Review
- Precision Medicine: An Emerging Paradigm for Improved Diagnosis and Safe Therapy in Pediatric Oncology.Cureus · 2021Review
- Multicenter study of risk factors of unplanned 30-day readmissions in pediatric oncology.Cancer reports (Hoboken, N.J.) · 2021Article
- Review
- Landscape of phase 1 clinical trials for minors with cancer in the United States.Pediatric blood & cancer · 2020Article
- Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.Cancer medicine · 2020Article
- Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.Journal of the National Cancer Institute · 2020Article
- Winning the RACE: Expanding pediatric cancer drug approvals.Pediatric blood & cancer · 2019Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well appreciated that the number of anticancer drugs approved for use in children is a fraction of the number approved for use in cancers that occur in adults. We address this fact by summarizing the relevant U.S. legislation that provides the framework for the evaluation and approval of drugs used to treat children with cancer. In total, the Food and Drug Administration (FDA) has approved 38 new drug applications for pediatric oncology indications, 12 of which were new molecular entities. FDA continues to collaborate with multistakeholders regarding the development of products intended for pediatric cancer and encourages the submission of marketing applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.